Tech Company Financing Transactions

Memo Therapeutics Funding Round

Adjuvant Capital, Fresenius Medical Care and GF Private Equity Group participated in a $22 million Series C capital raise for Memo Therapeutics. The financing round was announced by the company on 5/7/2024.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series C
Proceeds Purpose
The company intends to use the funds to bolster the clinical advancement of its lead asset, AntiBKV, expanding the Phase II trial with a dose evaluation extension.

Company Information

Company Status
Private & Independent
Healthcare Services
Mailing Address
Wagistrasse 27
Schlieren / Zurich, 8952
Email Address
Memo Therapeutics AG ("MTx") is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx' lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. AntiBKV has successfully completed Phase I with no safety concerns, with Phase II (POC) data expected in H1 2025. MTx' pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus ("CMV"), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical.
Memo Therapeutics LinkedIn Company Profile
Social Media
Memo Therapeutics Company Twitter Account
Company News
Memo Therapeutics News
Memo Therapeutics on Facebook
Memo Therapeutics on YouTube

Management Team

Email & Social
Elias Papatheodorou
  Elias Papatheodorou LinkedIn Profile  Elias Papatheodorou Twitter Account  Elias Papatheodorou News  Elias Papatheodorou on Facebook
Chief Executive Officer
Erik Van Den Berg
  Erik Van Den Berg LinkedIn Profile  Erik Van Den Berg Twitter Account  Erik Van Den Berg News  Erik Van Den Berg on Facebook
Chief Financial Officer
Lars Spenger
  Lars Spenger LinkedIn Profile  Lars Spenger Twitter Account  Lars Spenger News  Lars Spenger on Facebook
Chief Marketing Officer
Jürgen Beck
  Jürgen Beck LinkedIn Profile  Jürgen Beck Twitter Account  Jürgen Beck News  Jürgen Beck on Facebook
Chief Scientific Officer
Christoph Esslinger
  Christoph Esslinger LinkedIn Profile  Christoph Esslinger Twitter Account  Christoph Esslinger News  Christoph Esslinger on Facebook
Vice President
Maartje Verschuur
  Maartje Verschuur LinkedIn Profile  Maartje Verschuur Twitter Account  Maartje Verschuur News  Maartje Verschuur on Facebook
VP - Bus. Development
Gerald Parzmair
  Gerald Parzmair LinkedIn Profile  Gerald Parzmair Twitter Account  Gerald Parzmair News  Gerald Parzmair on Facebook
VP - Operations
Kristie Clemmer
  Kristie Clemmer LinkedIn Profile  Kristie Clemmer Twitter Account  Kristie Clemmer News  Kristie Clemmer on Facebook
VP - Operations
Simone Schmitt
  Simone Schmitt LinkedIn Profile  Simone Schmitt Twitter Account  Simone Schmitt News  Simone Schmitt on Facebook



Browse more venture capital transactions:

Prev: 5/7/2024: Acclinate venture capital transaction
Next: 5/7/2024: Inkbit venture capital transaction


Share this article


Where The Data Comes From

We do our best to document all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary